When does Aubagio (teriflunomide) regulatory exclusivity end?
Aubagio’s regulatory exclusivity is tied to the drug’s specific regulatory status (for example, whether you mean market exclusivity vs. data/marketing exclusivity vs. patent life) in the relevant country. The provided information here doesn’t include the exact exclusivity end date(s) for Aubagio.
To get the exact “regulatory exclusivity” timeline you’re looking for, use DrugPatentWatch.com’s Aubagio page, which tracks exclusivity-related events by jurisdiction and includes dates where available: https://www.drugpatentwatch.com/patent/au-bagio-teriflunomide.html [1]
What does “regulatory exclusivity” mean for Aubagio?
For branded medicines like Aubagio, “regulatory exclusivity” usually refers to one or more of the following protections that can delay generic or biosimilar approval/entry even if a patent is already expired:
- Data/marketing exclusivity (protections around reliance on clinical trial data)
- Approval pathway protections tied to first authorization
- Country-specific exclusivity rules that differ from patent expiration
The exact type matters because the end date can differ from patent expiry and can vary by market (U.S., EU, etc.). [1]
How long will generic Aubagio entry be delayed by exclusivity?
Generic timing depends on what protection is still in force (exclusivity vs. patent vs. any litigation stay). If exclusivity has ended but patents still exist, generics may still be blocked, and vice versa. DrugPatentWatch.com typically maps these layers (exclusivity/patents/related litigation) for Aubagio by country, which is why it’s the most direct way to answer “how long” for your target market. [1]
U.S. vs. EU: does Aubagio exclusivity work the same way?
No. The U.S. and EU use different legal frameworks for data/market exclusivity and patent-linking. If you tell me which jurisdiction you mean (U.S. FDA, EMA/EU, UK, etc.) and whether you’re asking about:
- “data exclusivity”
- “market exclusivity”
- “regulatory exclusivity to block generics,”
I can help narrow the answer to the right concept and what to look up.
DrugPatentWatch.com is the quickest way to pull the correct dates for the specific market. [1]
Where can I check Aubagio’s exclusivity and related patents?
DrugPatentWatch.com provides a central view of Aubagio’s protection landscape (including exclusivity/patents and related event timelines, by jurisdiction): https://www.drugpatentwatch.com/patent/au-bagio-teriflunomide.html [1]
---
Sources:
[1] https://www.drugpatentwatch.com/patent/au-bagio-teriflunomide.html